Quantitative profiling of the protein coronas that form around nanoparticles

Nature Protocols

Volumn 9, Issue 9, 2014, Pages 2030-2044

  Docter, Dominic ^a   Distler, Ute ^a   Storck, Wiebke ^a   Kuharev, Jörg ^a   Wünsch, Desirée ^a   Hahlbrock, Angelina ^a   Knauer, Shirley K ^b   Tenzer, Stefan ^a   Stauber, Roland H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; POLYSTYRENE DERIVATIVE; PROTEIN; SILICON DIOXIDE; SUCROSE; TRYPSIN;

ANIMAL; CHEMICAL ANALYSIS; CHEMISTRY; ELECTROPHORESIS; FRACTIONATION; ISOLATION AND PURIFICATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; PROCEDURES;

ANIMALS; CHEMICAL FRACTIONATION; CHEMISTRY TECHNIQUES, ANALYTICAL; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS; MASS SPECTROMETRY; MICE; NANOPARTICLES; POLYSTYRENES; PROTEINS; SILICON DIOXIDE; SUCROSE; TRYPSIN;

EID: 84907029383     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2014.139     Document Type: Article

References (51)

1. Reese, M. Nanotechnology: using co-regulation to bring regulation of modern technologies into the 21st century. Health Matrix Clevel. 23, 537-572 (2013).
2. Webster, T.J. Interview: Nanomedicine: past, present and future. Nanomedicine (Lond.) 8, 525-529 (2013).
3. Nystrom, A.M. & Fadeel, B. Safety assessment of nanomaterials: implications for nanomedicine. J. Control Release 161, 403-408 (2012).
4. Oberdorster, G. Nanotoxicology: in vitro-in vivo dosimetry. Environ. Health Perspect. 120, A13 (2012).
5. Rauscher, H., Sokull-Kluttgen, B. & Stamm, H. The European Commission's recommendation on the definition of nanomaterial makes an impact. Nanotoxicology 7, 1195-1197 (2013).
6. Monopoli, M.P., Aberg, C., Salvati, A. & Dawson, K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779-786 (2012).
7. Monopoli, M.P., Bombelli, F.B. & Dawson, K.A. Nanobiotechnology: nanoparticle coronas take shape. Nat. Nanotechnol. 6, 11-12 (2011).
8. Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772-781 (2013).
9. Capriotti, A.L. et al. DNA affects the composition of lipoplex protein corona: a proteomics approach. Proteomics 11, 3349-3358 (2012).
10. Xia, X.R., Monteiro-Riviere, N.A. & Riviere, J.E. An index for characterization of nanomaterials in biological systems. Nat. Nanotechnol. 5, 671-675 (2010).
11. Nel, A.E. et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543-557 (2009).
12. Tenzer, S. et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 5, 7155-7167 (2011).
13. Zhang, H. et al. Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size. Proteomics 11, 4569-4577 (2011).
14. Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol 8, 137-143 (2013).
15. Wegner, K.D., Jin, Z., Linden, S., Jennings, T.L. & Hildebrandt, N. Quantum dot-based Forster resonance energy transfer immunoassay for sensitive clinical diagnostics of low-volume serum samples. ACS Nano 7, 7411-7419 (2013).
16. Barkam, S., Saraf, S. & Seal, S. Fabricated micro-nano devices for in vivo and in vitro biomedical applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5, 544-568 (2013).
17. Dobrovolskaia, M.A., Germolec, D.R. & Weaver, J.L. Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 4, 411-414 (2009).
18. Distler, U. et al. Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. Nat. Methods 11, 167-170 (2014).
19. Meister, S. et al. Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model. Alzheimer's Res. Ther. 5, 51 (2013).
20. Evans, C. et al. An insight into iTRAQ: where do we stand now? Anal. Bioanal. Chem. 404, 1011-1027 (2012).
21. Bantscheff, M., Lemeer, S., Savitski, M.M. & Kuster, B. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Anal. Bioanal. Chem. 404, 939-965 (2012).
22. Tate, S., Larsen, B., Bonner, R. & Gingras, A.C. Label-free quantitative proteomics trends for protein-protein interactions. J. Proteomics 81, 91-101 (2013).
23. Patel, V.J. et al. A comparison of labeling and label-free mass spectrometry-based proteomics approaches. J. Proteome Res. 8, 3752-3759 (2009).
24. Cai, X. et al. Characterization of carbon nanotube protein corona by using quantitative proteomics. Nanomedicine 9, 583-593 (2013).
25. Farrah, T. et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics 10, M110.006353 (2011).
26. Nahnsen, S., Bielow, C., Reinert, K. & Kohlbacher, O. Tools for label-free peptide quantification. Mol. Cell. Proteomics 12, 549-556 (2013).
27. Gethings, L.A. & Connolly, J.B. Simplifying the proteome: analytical strategies for improving peak capacity. Adv. Exp. Med. Biol. 806, 59-77 (2014).
28. Gebauer, J.S. et al. Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir 28, 9673-9679 (2012).
29. Walczyk, D., Bombelli, F.B., Monopoli, M.P., Lynch, I. & Dawson, K.A. What the cell 'sees' in bionanoscience. J. Am. Chem. Soc. 132, 5761-5768 (2010).
30. Casals, E., Pfaller, T., Duschl, A., Oostingh, G.J. & Puntes, V. Time evolution of the nanoparticle protein corona. ACS Nano 4, 3623-3632 (2010).
31. Dell'Orco, D., Lundqvist, M., Oslakovic, C., Cedervall, T. & Linse, S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS ONE 5, e10949 (2010).
32. Barran-Berdon, A.L. et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 29, 6485-6494 (2013).
33. Natte, K. et al. Impact of polymer shell on the formation and time evolution of nanoparticle-protein corona. Colloids Surf. B Biointerfaces 104, 213-220 (2013).
34. Rocker, C., Potzl, M., Zhang, F., Parak, W.J. & Nienhaus, G.U. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat. Nanotechnol. 4, 577-580 (2009).
35. Lundqvist, M. et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 5, 7503-7509 (2011).
36. Owens, D.E. III & Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102 (2006).
37. Mahmoudi, M. et al. Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles. Nanoscale 3, 1127-1138 (2011).
38. Ehrenberg, M.S., Friedman, A.E., Finkelstein, J.N., Oberdorster, G. & McGrath, J.L. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30, 603-610 (2009).
39. Gessner, A., Lieske, A., Paulke, B. & Muller, R. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur. J. Pharm. Biopharm. 54, 165-170 (2002).
40. Dobrovolskaia, M.A. et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (Lond.) 5, 106-117 (2009).
41. Lundqvist, M. et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. USA 105, 14265-14270 (2008).
42. Chakraborty, S. et al. Contrasting effect of gold nanoparticles and nanorods with different surface modifications on the structure and activity of bovine serum albumin. Langmuir 27, 7722-7731 (2011).
43. Dutta, D. et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol. Sci. 100, 303-315 (2007).
44. Cedervall, T. et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem. Int. Ed. Engl. 46, 5754-5756 (2007).
45. Lacerda, S.H. et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 4, 365-379 (2010).
46. Lindman, S. et al. Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett. 7, 914-920 (2007).
47. Mahmoudi, M. et al. Temperature: the 'ignored' factor at the NanoBio interface. ACS Nano 7, 6555-6562 (2013).
48. Mahmoudi, M., Laurent, S., Shokrgozar, M.A. & Hosseinkhani, M. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell 'vision' versus physicochemical properties of nanoparticles. ACS Nano 5, 7263-7276 (2011).
49. Monopoli, M.P. et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133, 2525-2534 (2011).
50. Goppert, T.M. & Muller, R.H. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm. 60, 361-372 (2005).
51. Labarre, D. et al. Interactions of blood proteins with poly(isobutylcyanoac rylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 26, 5075-5084 (2005).